Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea
et al., medRxiv, doi:10.1101/2020.05.13.20094193, May 2020
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HCQ+antibiotic. Preprint withdrawn pending peer review.
|
hospitalization time, 51.0% lower, relative time 0.49, p = 0.01, treatment 22, control 40.
|
|
time to viral-, 56.0% lower, relative time 0.44, p = 0.005, treatment 22, control 40.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Kim et al., 18 May 2020, retrospective, South Korea, preprint, 12 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.05.13.20094193; this version posted June 14, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir,
and Antibiotics for Moderate COVID-19: A First Report on the
Pharmacological Outcomes from South Korea
Min Seo Kim, MD, Soon-Woo Jang, MD, KMD, Yu-Kyung Park, MD, Bong-Ok Kim, MD,
PhD, Tae-Ho Hwang, DSS, PhD, Seok Ho Kang, MD9, PhD, Won Jun Kim, MD, Park Sung
Kyu, MD, Hea-Woon Park, MD, PhD, Wonjong Yang, MD, Joonyoung Jang, MD, Min Ho
An, MD
The authors have withdrawn this manuscript because of the controversy about
hydroxychloroquine and potential changes in results after peer-review, the authors intend to
share their results in formal publication. Therefore, the authors do not wish this work to be
cited as reference for the project. If you have any questions, please contact the corresponding
author.
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
DOI record:
{
"DOI": "10.1101/2020.05.13.20094193",
"URL": "http://dx.doi.org/10.1101/2020.05.13.20094193",
"abstract": "<jats:p>The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.</jats:p>",
"accepted": {
"date-parts": [
[
2020,
6,
14
]
]
},
"author": [
{
"affiliation": [],
"family": "Kim",
"given": "Min Seo",
"sequence": "first"
},
{
"affiliation": [],
"family": "Jang",
"given": "Soon-Woo",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Park",
"given": "Yu-Kyung",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kim",
"given": "Bong-Ok",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hwang",
"given": "Tae-Ho",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kang",
"given": "Seok Ho",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kim",
"given": "Won Jun",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kyu",
"given": "Park Sung",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Park",
"given": "Hea-Woon",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Yang",
"given": "Wonjong",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Jang",
"given": "Joonyoung",
"sequence": "additional"
},
{
"affiliation": [],
"family": "An",
"given": "Min Ho",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
5,
18
]
],
"date-time": "2020-05-18T20:25:13Z",
"timestamp": 1589833513000
},
"deposited": {
"date-parts": [
[
2021,
1,
4
]
],
"date-time": "2021-01-04T06:50:14Z",
"timestamp": 1609743014000
},
"group-title": "Infectious Diseases (except HIV/AIDS)",
"indexed": {
"date-parts": [
[
2023,
9,
2
]
],
"date-time": "2023-09-02T01:30:47Z",
"timestamp": 1693618247422
},
"institution": [
{
"name": "medRxiv"
}
],
"is-referenced-by-count": 12,
"issued": {
"date-parts": [
[
2020,
5,
18
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2020.05.13.20094193",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2020,
5,
18
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2020,
5,
18
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://medrxiv.org/lookup/doi/10.1101/2020.05.13.20094193"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subtitle": [],
"subtype": "preprint",
"title": "Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea",
"type": "posted-content"
}
Late treatment
is less effective
is less effective
